Our core business is the chemical synthesis of peptides and the custom production of polyclonal antibodies.

Peptides and antibodies are different forms of proteins. As proteins control every process essential for life, discovering more about how they work and how they help the body fight disease and infection, is crucial for furthering medical research, drug development and health care provision.

All CRB’s products are used purely for medical research purposes — primarily drug discovery and disease research — either by commercial organisations or academic institutes. We do not sell them to be used directly on patients.

Alongside this custom-production, we also ‘partner’ small, highly specialised biochemical businesses to help them promote their services and gain wider exposure.  

Organisation type

Canbex Therapeutics Ltd United Kingdom

Canbex Therapeutics is dedicated to treating spasticity in multiple sclerosis (MS) and other disorders. Spasticity is a debilitating and painful symptom that consists of involuntary spasms and stiffness of limbs and torso. The goal of the Canbex lead programme is to improve the lives of people with this serious and incurable disorder, and set a new standard in the treatment of spasticity.

The company’s lead compound, VSN16R, is currently in a Phase II study to determine its efficacy in relieving spasticity in people with MS. VSN16R was shown to be safe and well tolerated in a Phase I human safety trial in healthy volunteers that was completed in 2014.

Organisation type
Dr Keith Powell
LinkedIn logo Chairman 
Dr Jesse Schulman

Cell and Gene Therapy Catapult United Kingdom

The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Supported by Innovate UK, our mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies.

Organisation type
Dr Almira Bartolome
BD Europe 
Dr Sarah Maxfield
Business Development 

CIMYM BioSciences United Kingdom

CIMYM BioSciences was established to develop oncology and immunological therapeutics.  At CIMYM we believe passionately that drug development can only be successful if it is patient centred…’Begin with the patient in mind'. As a healthcare company we recognise an exceptional idea to fill a medical need, build a network and then establish a clinical utility that will improve patient care.  CIMYM uses its expertise to manage value-enhancing activities in the development process of pharmaceuticals and diagnostics. It takes a patient-centred approach to co-develop these innovative products and in turn licenses the rights for manufacture and marketing to other pharmaceutical companies.

Organisation type
Ms Yvonne Joseph
Ms Yvonne Joseph
LinkedIn logo Managing Director 

Crescendo Biologics Ltd United Kingdom

Crescendo has developed a novel antibody fragment platform which generates fully human VH products, the smallest antibody fragments, that mature in vivo in a transgenic mouse. The company has a highly experienced antibody drug discovery team and capability. Crescendo is using the platform to develop a portfolio of differentiated medicines, with an initial focus on novel topical products, and is identifying companies interested in partnering this platform.

Organisation type
Dr Nigel Crockett
LinkedIn logo Head Business Development 
Dr Peter Pack
LinkedIn logo CEO 

High Force Research United Kingdom

Established in 1988, and based in Durham, High Force Research are proud to remain a truly independent UK chemistry CRO. We collaborate with discovery groups, start-ups and spin-offs from academia and industry in synthesising new materials for proof-of-concept studies and in process development on the route to market.

We have the expertise and capability to devise synthetic routes to new molecules or to identify and evaluate alternatives. Working at both bench-top and kilo-lab scale, we develop processes to meet our client's targets of yield, specification, safety, environmental impact and economics. Later we offer support in technology transfer to commercial production.

Our MHRA audited cGMP facilities comprise two segregated laboratories, in which we produce from grammes to multi-kilos of Active Pharmaceutical Ingredients and their intermediates to cGMP standards for pre-clinical studies and Phase I/II clinical trials.

We offer a fast response and flexible service to all our customers and partners and can operate on a fee for service, collaborative research or joint venture basis, depending on the project and business requirements.

Organisation type
Dr Stella James
LinkedIn logo Head of Business Development 

Karma Oncology Ltd United Kingdom

Oncology specialised contract clinical research organisation providing flexible, customised, bespoke services to the pharmaceutical and biotechnology industries. Oncology clinical research services including clinical development plan preparation, clinical trial protocol design & writing, site selection, project management, submissions, site set up and monitoring, data review, auditing and preparation of clinical study reports. We are looking to partner with companies with oncology products either about to enter the clinical phase of development or in the early stages of clinical development.

Organisation type
Dr Jennifer Emerson
Director of Project Managment 
Dr Karen Williams
LinkedIn logo President 

Propath UK Limited United Kingdom

Propath is a leader in Europe for histopathology and molecular pathology.  As a GLP and GCP compliant facility, our experience of regulatory and research studies spans over 30 years.

Organisation type
Dr Saroj Velamakanni
Director, Business Development 
Mr Edward Cribb
LinkedIn logo Client Relationships Executive 

Quay Pharmaceuticals ltd United Kingdom

Quay Pharma is one of the world’s leading Contract Development and Manufacturing Organisations, or CDMOs. Based in the UK, we provide specialist services to the pharmaceutical and biotech industries built on our unique expertise in drug formulation development, analytical services and contract manufacturing, MHRA and FDA inspected and approved.

Organisation type
Mr Michael Kruidenier
Head of Business Development 
Dr David Sykes
European Business Development Manager 

Seda Pharmaceutical Development Services United Kingdom

The integrated Pharmaceutical Development and Clinical Pharmacology Service that maximises value build.

We are based at Alderley Park, a centre of scientific excellence in the North of England.

By choosing Seda you can rest assured you are in safe hands. Our team have delivered high quality products, processes and regulatory submissions leading to the approval and launch of several successful medicines. We have practiced across therapeutic areas and have extensive experience in the development of Oncology drugs, including those with ‘breakthrough’ status.

Seda are pioneers of novel approaches to accelerate projects that can save you money and create better value. Our team of experts have deep scientific experience across a broad range of disciplines and stages of development, from discovery to launch.

Strategy > Design > Data > Interpretation > Execution

  • Consultancy
  • Physicochemical characterisation and preformulation studies
  • Solid form selection including polymorphs, salts and co-crystals
  • Preclinical safety study formulation development for challenging molecules
  • First-time-in-clinic and later phase / commercial formulation development
  • Enabling formulations and specialist drug delivery technology selection
  • Preclinical DMPK
  • Clinical pharmacokinetics and drug absorption including modeling
  • Due diligence, competitor analysis and technology opportunity assessments
  • Scientific leadership: academic - industry collaborations; training and mentoring; scientific advisory boards

Routes of administration and technology areas we cover:


  • Immediate release
  • Modified release
  • Oral poorly solubles

Standard Injectables 

Complex Injectables

  • Poorly soluble IV
  • Depot
  • Targeted

Nasal and Inhaled

Organisation type
Dr Paul Dickinson
Dr Paul Dickinson
LinkedIn logo Director 
Dr Marcel de Matas
Dr Marcel de Matas
LinkedIn logo Director